Table 5.

Genetic Model Parameters Estimated by AVENGEME, ABPA,^13,31 and GREML^13,32

	RA	CD	MI	T2D	SCZ ISC	SCZ PGC1	SCZ PGC2
AVENGEME ${\hat{\sigma }}_1^2$	.13 (.09–.17)	.28 (.21–.35)	.34 (.24–.45)	.30 (.23–.37)	.31 (.28–.34)	.31 (.29–.33)	.24 (.24–.25)
ABPA ${\hat{\sigma }}_1^2$	.18 (.11–.25)	.44 (.34–.54)	.48 (.32–.64)	.49 (.39–.59)	–	.50 (.45–.54)a	–
GREML ${\hat{\sigma }}_1^2$	.32 (.25–.39)	.33 (.25–.41)	.41 (.28–.54)	.51 (.38–.64)	.33 (.27–.39)	.23 (.21–.25)	–
AVENGEME ${\hat{\pi }}_{01}$	.946 (.887–.975)	.969 (.950–.982)	.965 (.933–.982)	.954 (.929–.971)	.953 (.940–.963)	.867 (.841–.887)	.852(.835–.867)
ABPA ${\hat{\pi }}_{01}$	.973 (.953–.993)	.972 (.954–.990)	.980 (.965–.995)	.962 (.941–.983)	–	.936 (.922–.952)a	–

95% confidence intervals given in parentheses, those for ABPA converted from the reported 50% credible intervals by assuming normally distributed posteriors and those for GREML from the reported standard error by assuming normally distributed estimators.

^aIncludes an additional Swedish case/control study.